Cat allergy immunotherapy - Circassia

Drug Profile

Cat allergy immunotherapy - Circassia

Alternative Names: Cat allergen vaccine - Circassia; Cat peptide allergen desensitisation; Cat Synthetic Peptide Immuno-Regulatory Epitopes; Cat-PAD; ToleroMune; ToleroMune Cat

Latest Information Update: 25 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Circassia
  • Class Allergens; Antiallergics; Cat allergy immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis
  • Discontinued Hypersensitivity

Most Recent Events

  • 18 Apr 2017 Efficacy data from the phase III trial in Allergic rhinoconjunctivitis released by Circassia Pharmaceuticals
  • 03 Mar 2017 Adverse events data from a phase II trial in Allergic rhinoconjunctivitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top